A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
The current price of AstraZeneca PLC in the market is ₩248,119.61, with a 24-hour trading volume of ₩466.49B. The asset's market cap is ₩384.8T, after moving 0.59% in the last day.
Tokenized AstraZeneca PLC is trading at ₩136,899.15, with a tokenized market cap of ₩77.5B and a 24-hour trading volume of ₩1.15B. The tokenized asset has moved -2.16% in the past 24 hours.